<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827983</url>
  </required_header>
  <id_info>
    <org_study_id>07EU/Prg06</org_study_id>
    <nct_id>NCT00827983</nct_id>
  </id_info>
  <brief_title>Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)</brief_title>
  <official_title>Efficacy and Tolerability of Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      Prospective, open, randomised, parallel, multicentre, two arm trial comparing a new form of
      luteal support (S.C.) to an approved comparator (vaginal gel).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Pregnancy Rate at the End of the Study</measure>
    <time_frame>10 weeks after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delivery Rate and Live Birth Rate</measure>
    <time_frame>nearly 9 month after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>Four to five weeks after oocytes retrieval</time_frame>
    <description>Implantation rate was defined as the mean of the total number of gestational sacs seen divided by the total number of embryos transferred. Values are reported as a percentage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">683</enrollment>
  <condition>In Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Progesterone SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone Vaginal gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>25 mg, s.c., once à day</description>
    <arm_group_label>Progesterone SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>90 mg, vaginally, once à day</description>
    <arm_group_label>Progesterone Vaginal gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18- 42 (upon starting COH);

          -  BMI &lt;30 kg/m2;

          -  &lt;3 prior ART cycles (IVF, ICSI and related procedures);

          -  Baseline (day 2-3 of cycling) FSH &lt;15 IU/L and E2 &lt;80 pg/mL;

          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or
             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);

          -  At least 3 retrieved oocytes;

          -  Patient has given written informed consent.

        Exclusion Criteria:

          -  Intramural uterine fibroids that distort the uterine cavity or polyps &gt;1 cm;

          -  Stage III or IV endometriosis (endometriomas);

          -  Hydrosalpinx;

          -  History of past poor response to COH resulting in canceling ART;

          -  Use of thawed/donated oocytes;

          -  Use of thawed/donated embryos;

          -  Patients affected by pathologies associated with any contraindication of being
             pregnant;

          -  Hypersensitivity to study medication;

          -  Uncontrolled adrenal or thyroid dysfunction;

          -  Undiagnosed vaginal bleeding;

          -  History of arterial disease;

          -  Patients with hepatic impairment;

          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;

          -  High grade cervical dysplasia;

          -  Active thrombophlebitis or thromboembolic disorders, or a history of
             hormone-associated thrombophlebitis or thromboembolic disorders;

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
             wherein pregnancy developed to a minimum of a gestational sac on TVUS;

          -  Participation in a concurrent clinical trial or another trial within the past 2
             months;

          -  Use of concomitant medications that might interfere with the study evaluation;

          -  Pre-implantation genetic diagnosis/screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinik fur Frauenheilkunde und Geburthilfe - Universistät zu Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Dept. Obstetric and Gynaecology, Semmelweiss University Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Ospedaliera di Ginecologia e Ostetricia, Ospedale Civico Brunico</name>
      <address>
        <city>Brunico</city>
        <state>Bolzano</state>
        <zip>39031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mangiagalli, Università di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Sanitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli 'Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara, Università degli studi di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IIRM SA</name>
      <address>
        <city>Sorengo</city>
        <state>Ticino</state>
        <zip>6924</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Fertility Services</name>
      <address>
        <city>Aldridge</city>
        <state>West Midlands</state>
        <zip>WS9 8LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital - Center for Reproductive Medicine</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' Hospital - Women's Health Department</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Bridge Center</name>
      <address>
        <city>London</city>
        <zip>SE1 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <results_first_submitted>November 26, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 26, 2012</results_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luteal Phase Support in IVF patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Progesterone SC</title>
          <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
        <group group_id="P2">
          <title>Progesterone Vaginal Gel</title>
          <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="339">All randomised patients</participants>
                <participants group_id="P2" count="344">all randomised patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="321">patients who performed the pregnancy test</participants>
                <participants group_id="P2" count="328">patients who performed the pregnancy test</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone SC</title>
          <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
        <group group_id="B2">
          <title>Progesterone Vaginal Gel</title>
          <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="339"/>
            <count group_id="B2" value="344"/>
            <count group_id="B3" value="683"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="4.3"/>
                    <measurement group_id="B2" value="33.9" spread="4.3"/>
                    <measurement group_id="B3" value="33.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ongoing Pregnancy Rate at the End of the Study</title>
        <time_frame>10 weeks after treatment start</time_frame>
        <population>ITT population was analysed (i.e. all the randomised patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Vaginal Gel</title>
            <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy Rate at the End of the Study</title>
          <population>ITT population was analysed (i.e. all the randomised patients)</population>
          <units>percentage of randomized patient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="-9.9%"/>
                    <measurement group_id="O2" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The non -inferiority hypothesis to be tested for the primary endpoint was that the ongoing pregnancy rate (oPR) in the test group (Pe)was lower than the oPR in the control group (Pc)against the alternative one that the oPR in the test group was equal to or higher than the oPR in the control group.
H0 : Pc&gt;= Pe + d(-10%) H1 : Pc&lt; Pe + d(-10%)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis (H0) was tested against the alternative by calculating a two-sided 95% confidence interval for the difference in ongoing pregnancy rates. If the lower bound of the 95% confidence interval was greater than the non-inferiority limit (-10.0%), the null hypothesis was rejected and the test group considered not inferior to the control treatment.</non_inferiority_desc>
            <p_value>0.37</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in pregnancy rates</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delivery Rate and Live Birth Rate</title>
        <time_frame>nearly 9 month after treatment start</time_frame>
        <population>all the randomised patients were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Vaginal Gel</title>
            <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
        </group_list>
        <measure>
          <title>Delivery Rate and Live Birth Rate</title>
          <population>all the randomised patients were included in the analysis</population>
          <units>percentage of randomised patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.87</ci_lower_limit>
            <ci_upper_limit>3.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implantation Rate</title>
        <description>Implantation rate was defined as the mean of the total number of gestational sacs seen divided by the total number of embryos transferred. Values are reported as a percentage.</description>
        <time_frame>Four to five weeks after oocytes retrieval</time_frame>
        <population>All the patients who had at least one embryo transferred</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Vaginal Gel</title>
            <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
          </group>
        </group_list>
        <measure>
          <title>Implantation Rate</title>
          <description>Implantation rate was defined as the mean of the total number of gestational sacs seen divided by the total number of embryos transferred. Values are reported as a percentage.</description>
          <population>All the patients who had at least one embryo transferred</population>
          <units>percentage of embryos transferred</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="35.0"/>
                    <measurement group_id="O2" value="23.1" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 10 weeks of treatment, with a follow-up period of 6 months</time_frame>
      <desc>All the patients who received at least one dose of the study drug have been included in the adverse event analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Progesterone SC</title>
          <description>Progesterone SC was administered at a daily dosage of 25 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
        <group group_id="E2">
          <title>Progesterone Vaginal Gel</title>
          <description>Progesterone Vaginal gel was administered at a daily dosage of 90 mg during a minimum of two weeks (in case of no pregnancy) to a maximum of 10 weeks (in case of pregnancy)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="338"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OHSS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="338"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="338"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="338"/>
                <counts group_id="E2" events="34" subjects_affected="16" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="168" subjects_affected="168" subjects_at_risk="338"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Administration site pruritus</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="338"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>administration site swelling</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="338"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="338"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="338"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>vaginal hemorrage</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="338"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vaginal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="338"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>no special limitations of the trial were detected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical trial manager</name_or_title>
      <organization>IBSA Institut biochimique</organization>
      <phone>+41583601000</phone>
      <email>barbara.cometti@ibsa.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

